Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Moderna launches two new mRNA vaccine programmes

0
SHARES

The new mRNA vaccine programmes are aimed at the major causative agents of respiratory tract infections, respiratory syncytial virus (RSV), influenza and coronaviruses.

idea of mRNA vaccine development - vaccine and a SARS-CoV-2 virus wrapped by an mRNA strand

Moderna has announced that it will expand its messenger RNA (mRNA) pipeline with two new development programmes, one for a combination respiratory vaccine candidate and the other against all four of the endemic human coronaviruses (HCoV).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The enterprise stated the announcement “reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax®, its COVID-19 vaccine”.

As part of advancing a portfolio of respiratory candidates, Moderna is launching a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults: SARS-CoV-2 virus (the cause of COVID-19), influenza virus and respiratory syncytial virus (RSV). The new combination respiratory vaccine candidate (mRNA-1230) is envisioned as an annual booster vaccine.

The second programme is developing a vaccine candidate (mRNA-1287) against HCoVs. While less-well known than other coronaviruses, HCoVs are a significant cause of respiratory disease worldwide. Four HCoVs (HCoV-229E, -NL63, -OC43, and -HKU1) are endemic globally, accounting for approximately 10 to 30 percent of upper respiratory tract infections in adults.

“We are pleased to add a combination respiratory vaccine candidate against three of the leading causes of respiratory disease in older adults, and a vaccine against all four of the endemic human coronaviruses as part of our strategy to address the substantial global burden of respiratory infections,” stated Dr Stephen Hoge, President of Moderna. “Our goal is to develop vaccines to address respiratory infections, and eventually combine many into a single annual booster vaccine with the aim of reducing the significant morbidity and mortality caused by these viruses.”

Respiratory tract infections are a major public health problem, and these development programmes are aimed at the major causative agents. Coronaviruses, seasonal influenza and RSV all take a substantial toll on human health, particularly among older adults who experience more severe illness and greater mortality than younger adults.

mRNA vaccine candidates for HIV enter Phase I trial…

Share via
Share via